Literature DB >> 11368380

Who should be transplanted for AML?

F R Appelbaum1.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11368380     DOI： 10.1038/sj.leu.2402074

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Yu-Hong Chen; Yu Wang; Wei Han; Huan Chen
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

2.  Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.

Authors:  Mohamad Mohty; Florent Malard; Didier Blaise; Noel Milpied; Gérard Socié; Anne Huynh; Oumédaly Reman; Ibrahim Yakoub-Agha; Sabine Furst; Thierry Guillaume; Resa Tabrizi; Stéphane Vigouroux; Pierre Peterlin; Jean El-Cheikh; Philippe Moreau; Myriam Labopin; Patrice Chevallier
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

3.  Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI.

Authors:  Christian Späth; Christoph Busemann; William H Krüger
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.